Nadia Howlader1,2, Angela B Mariotto1, Caroline Besson3, Gita Suneja4, Kim Robien2, Naji Younes2, Eric A Engels5. 1. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. 2. Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC. 3. Faculty of Medicine, University of Paris Sud, Le Kremlin-Bicêtre, France. 4. Department of Radiation Oncology, University of Utah, Salt Lake City, Utah. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Abstract
BACKGROUND: Survival after the diagnosis of diffuse large B-cell lymphoma (DLBCL) has been increasing since 2002 because of improved therapies; however, long-term outcomes for these patients in the modern treatment era are still unknown. METHODS: Using Surveillance, Epidemiology, and End Results data, this study first assessed factors associated with DLBCL-specific mortality during 2002-2012. An epidemiologic risk profile, based on clinical and demographic characteristics, was used to stratify DLBCL cases into low-, medium-, and high-risk groups. The proportions of DLBCL cases that might be considered cured in these 3 risk groups was estimated. Risks of death due to various noncancer causes among DLBCL cases versus the general population were also calculated with standardized mortality ratios (SMRs). RESULTS: Overall, 8274 deaths were recorded among 18,047 DLBCL cases; 76% of the total deaths were attributed to DLBCL, and 24% were attributed to noncancer causes. The 10-year survival rates for the low-, medium-, and high-risk groups were 80%, 60%, and 36%, respectively. The estimated cure proportions for the low-, medium-, and high-risk groups were 73%, 49%, and 27%, respectively; however, these cure estimates were uncertain because of the need to extrapolate the survival curves beyond the follow-up time. Mortality risks calculated with SMRs were elevated for conditions including vascular diseases (SMR, 1.3), infections (SMR, 3.1), gastrointestinal diseases (SMR, 2.5), and blood diseases (SMR, 4.6). These mortality risks were especially high within the initial 5 years after the diagnosis and declined after 5 years. CONCLUSIONS: Some DLBCL patients may be cured of their cancer, but they continue to experience excess mortality from lymphoma and other noncancer causes. Cancer 2017;123:3326-34.
BACKGROUND: Survival after the diagnosis of diffuse large B-cell lymphoma (DLBCL) has been increasing since 2002 because of improved therapies; however, long-term outcomes for these patients in the modern treatment era are still unknown. METHODS: Using Surveillance, Epidemiology, and End Results data, this study first assessed factors associated with DLBCL-specific mortality during 2002-2012. An epidemiologic risk profile, based on clinical and demographic characteristics, was used to stratify DLBCL cases into low-, medium-, and high-risk groups. The proportions of DLBCL cases that might be considered cured in these 3 risk groups was estimated. Risks of death due to various noncancer causes among DLBCL cases versus the general population were also calculated with standardized mortality ratios (SMRs). RESULTS: Overall, 8274 deaths were recorded among 18,047 DLBCL cases; 76% of the total deaths were attributed to DLBCL, and 24% were attributed to noncancer causes. The 10-year survival rates for the low-, medium-, and high-risk groups were 80%, 60%, and 36%, respectively. The estimated cure proportions for the low-, medium-, and high-risk groups were 73%, 49%, and 27%, respectively; however, these cure estimates were uncertain because of the need to extrapolate the survival curves beyond the follow-up time. Mortality risks calculated with SMRs were elevated for conditions including vascular diseases (SMR, 1.3), infections (SMR, 3.1), gastrointestinal diseases (SMR, 2.5), and blood diseases (SMR, 4.6). These mortality risks were especially high within the initial 5 years after the diagnosis and declined after 5 years. CONCLUSIONS: Some DLBCL patients may be cured of their cancer, but they continue to experience excess mortality from lymphoma and other noncancer causes. Cancer 2017;123:3326-34.
Keywords:
Surveillance, Epidemiology, and End Results (SEER); cancer-specific survival; causes of death; cure; diffuse large B-cell lymphoma; noncancer causes of death; rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); standardized mortality ratio
Authors: Sourabh Shukla; Anne Jessica Roe; Ruifu Liu; Frank A Veliz; Ulrich Commandeur; David N Wald; Nicole F Steinmetz Journal: Biomater Sci Date: 2020-06-17 Impact factor: 6.843
Authors: Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen Journal: Expert Opin Investig Drugs Date: 2017-12-24 Impact factor: 6.206
Authors: R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff Journal: Expert Rev Hematol Date: 2019-09-12 Impact factor: 2.929
Authors: Qian Shi; Norbert Schmitz; Fang-Shu Ou; Jesse G Dixon; David Cunningham; Michael Pfreundschuh; John F Seymour; Ulrich Jaeger; Thomas M Habermann; Corinne Haioun; Hervé Tilly; Hervé Ghesquieres; Francesco Merli; Marita Ziepert; Raoul Herbrecht; Jocelyne Flament; Tommy Fu; Bertrand Coiffier; Christopher R Flowers Journal: J Clin Oncol Date: 2018-07-05 Impact factor: 44.544
Authors: Toby A Eyre; William Wilson; Amy A Kirkwood; Julia Wolf; Catherine Hildyard; Hannah Plaschkes; John Griffith; Paul Fields; Arief Gunawan; Rebecca Oliver; Stephen Booth; Jaimal Kothari; Christopher P Fox; Nicolas Martinez-Calle; Andrew McMillan; Mark Bishton; Graham P Collins; Chris S R Hatton Journal: Blood Adv Date: 2021-04-27